奥马佐单抗治疗过敏性支气管哮喘疗效与安全性的系统评价

摘要

目的 探讨奥马佐单抗治疗过敏性支气管哮喘的临床疗效及安全性.方法 将我院呼吸道门诊收治的112例过敏性支气管哮喘患者分为实验组和对照组,实验组给予奥马佐单抗加糖皮质激素治疗,对照组口服安慰剂或适量糖皮质激素治疗,观察两组治疗前后第1秒时间肺活量(FEV1)、最大呼气流速(PEF)、V 25％～75％等肺功能指标变化,比较两组临床疗效及不良反应.结果 两组治疗后FEV1、V25％～75％和PEF等三项肺功能指标均较治疗前有所改善(P＜0.05),但实验组改善幅度明显优于对照组(P＜ 0.05).实验组治疗总有效率93.3％,显著高于对照组的84.6％ (P＜0.05).实验组2例不良反应,对照组4例,对比差异无统计学意义(P＞0.05).结论 奥马佐单抗可有效缓解过敏性支气管哮喘症状,改善生活质量,安全性好,值得临床推广应用.%Objective To investigate clinical efficacy and safety of Omalizumab in the treatment of allergic bronchial asthma.Methods 112 cases of allergic bronchial asthma in respiratory department of internal medicine of our hospital were divided into experimental group and control group.Experimental group was given Omalizumab combined with glucocorticoids therapy,while control group was given placebo or moderate amount of glucocorticoids.Observed FEV1,peak expiratory flow (PEF),V25％-75％ and other changes in lung function of two groups before and after treatment,compared clinical efficacy and adverse reactions between two groups.Results After treatment,FEV1,PEF,V25％-75％ in both two groups improved (P＜0.05),and the extent of improvement in experimental group was superior to that in control group (P＜0.05).The total effective rate of experimental group was 93.3％,significantly higher than 84.6％ of control group (P＜0.05).There were 2 cases of adverse reactions in experimental group,and 4 cases in control group,without statistically significant difference (P＞0.05).Conclusion Omalizumab can efficiently relieve patients' allergic bronchial asthma symptoms,improve quality of life,which is safe,worthy of clinical application.